US Patent 12091461 Bispecific antibody
Patent 12091461 was granted and assigned to ONO PHARMACEUTICAL CO., LTD. on September, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+28 properties)
Article (+541 characters)
US Patent 12091461 Bispecific antibody
Article
Patent abstract
A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Cornelis Adriaan de Kruif0
Mark Throsby0
Pieter Fokko van Loo0
Rinse Klooster0
Shiro Shibayama0
Takuya Shimbo0
Tomoya Tezuka0
Date of Patent
September 17, 2024
0Patent Application Number
173668780
Date Filed
July 2, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 12091461 Bispecific antibody
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
